PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol–gels for drug delivery

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 191-201

  Cho, Hyunah ^a   Gao, Jieming ^b   Kwon, Glen S ^b,c  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Block copolymer; Controlled release; Drug combination; Drug solubilization; Hydrogels; Polymeric micelles; Prodrugs

Indexed keywords

BLOCK COPOLYMERS; GELS; HYDROGELS; LACTIC ACID; POLYETHYLENE GLYCOLS; SOL-GELS;

CONTROLLED RELEASE; DRUG COMBINATIONS; DRUG SOLUBILIZATION; POLYMERIC MICELLE; PRODRUGS;

MICELLES;

COPOLYMER; PACLITAXEL; POLY(ETHYLENE GLYCOL) BLOCK POLY(LACTIC ACID); POLY(LACTIC CO GLYCOLIC ACID) BLOCK POLY(ETHYLENE GLYCOL) BLOCK POLY(LACTIC CO GLYCOLIC ACID); UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTIC ACID DERIVATIVE; MACROGOL DERIVATIVE; POLY(LACTIC ACID-ETHYLENE GLYCOL); POLY(LACTIDE-CO-GLYCOLIDE)-BLOCK-POLY(ETHYLENE GLYCOL)-BLOCK-POLY(LACTIDE-CO-GLYCOLIDE); POLYESTER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SOLUBILITY; HUMAN; HYDROGEL; MELANOMA; MICELLE; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; GEL; METABOLISM; NEOPLASM; PHASE TRANSITION; PROCEDURES; SOLUBILITY; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DELIVERY SYSTEMS; GELS; HUMANS; LACTATES; MICELLES; NEOPLASMS; PACLITAXEL; PHASE TRANSITION; POLYESTERS; POLYETHYLENE GLYCOLS; SOLUBILITY;

EID: 84950336552     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.12.015     Document Type: Article

References (68)

1. [1] Al-Lazikani, B., Banerji, U., Workman, P., Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 20 (2012), 1–13.
2. [2] Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer research. Nat. Rev. Cancer 12 (2012), 237–251.
3. [3] Decker, S., Sausville, E.A., Preclinical model of combination treatments: fantasy or requirement?. Ann. N. Y. Acad. Sci. 1059 (2005), 61–69.
4. [4] Woodcock, J., Griffin, J.P., Behrman, R.E., Development of novel combination therapies. N. Engl. J. Med. 364 (2011), 985–987.
5. [5] Sausville, E.A., Respecting cancer drug transportability: a basis for lead selection. J. Natl. Cancer Inst. 98 (2006), 1098–1099.
6. [6] Wang, J., Lu, Z., Gao, Y., Wientjes, M.G., Au, J.L., Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine 6 (2011), 1605–1620.
7. [7] Mayer, L.D., Harasym, T.O., Tardi, P.G., Harasym, N.L., Shew, C.R., Johnstone, S.A., Ramsay, E.C., Bally, M.B., Janoff, A.S., Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5 (2006), 1854–1863.
8. [8] Gaucher, G., Marchessault, R.H., Leroux, J.-C., Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J. Control. Release 143 (2010), 2–12.
9. [9] Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
10. [10] Discher, D.E., Ahmed, F., Polymersomes. Annu. Rev. Biomed. Eng. 8 (2006), 323–341.
11. [11] Jeong, B., Kim, S.W., Bae, Y.H., Thermosensitive sol–gel reversible hydrogels. Adv. Drug Deliv. Rev. 54 (2002), 37–51.
12. [12] Hu, C.J., Aryal, S., Zhang, L., Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1 (2010), 323–334.
13. [13] Zhang, H., Wang, G., Yang, H., Drug delivery systems for differential release in combination therapy. Expert Opin. Drug Deliv. 8 (2011), 171–190.
14. [14] Kwon, G.S., Polymeric Micelles for Multiple-Drug Delivery. Svenson, S., Prud'homme, R.K., (eds.) Multifunctional Nanoparticles for Drug Delivery Applications, 2012, Springer, New York, 133–152.
15. [15] Cho, H., Lai, T.C., Tomoda, K., Kwon, G.S., Polymeric micelles for multidrug delivery in cancer. AAPS PharmSciTech 19 (2015), 10–20.
16. [16] Kataoka, K., Kwon, G.S., Yokoyama, M., Okano, T., Sakurai, Y., Block copolymer micelles as vehicles for drug delivery. J. Control. Release 24 (1993), 119–132.
17. [17] Lavasanifar, A., Samuel, J., Kwon, G.S., Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 54 (2002), 169–190.
18. [18] Adams, M.L., Lavasanifar, A., Kwon, G.S., Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 92 (2003), 1343–1355.
19. [19] Matsumura, Y., The discovery of nanomedicine and its clinical experience. Jpn. J. Clin. Oncol. 44 (2014), 515–525.
20. [20] Eetezadi, S., Ekdawi, S.N., Allen, C., The challenges facing block copolymer micelles for cancer therapy: in vivo barriers and clinical translation. Adv. Drug Deliv. Rev. 91 (2015), 7–22.
21. [21] J. R. Churchill, F. Hutchinson, Biodegradable Amphipathic Copolymers, European patent application 85304489.9.
22. [22] Piskin, E., Kaitian, X., Denkbas, E.B., Kucukyavuz, Z., Novel PDLLA/PEG copolymer micelles as drug carriers. J. Biomater. Sci. Polym. Ed. 7 (1995), 359–373.
23. [23] Zhang, X., Jackson, J.K., Burt, H.M., Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int. J. Pharm. 132 (1996), 195–206.
24. [24] Lee, S.-W., Yun, M.-H., Jeong, S.W., In, C.-H., Kim, J.-Y., Seo, M.-H., Pai, C.-M., Kim, S.-O., Development of docetaxel-loaded intravenous formulation, nanoxel-pm™ using polymer-based delivery system. J. Control. Release 155 (2011), 262–271.
25. [25] Shin, H.-C., Alani, A.W.G., Rao, D.A., Rockich, N.C., Kwon, G.S., Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release 140 (2009), 294–300.
26. [26] Shin, H.-C., Alani, A.W.G., Cho, H., Bae, Y., Kolesar, J.M., Kwon, G.S., A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol. Pharm. 8 (2011), 1257–1265.
27. [27] Xiong, M.P., Yanez, J.A., Kwon, G.S., Davies, N.M., Forrest, M.L., A cremophor-free formulation of tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. J. Pharm. Sci. 98 (2009), 1577–1586.
28. [28] Danquah, M., Li, F., Duke, C.B. III, Miller, D.D., Mahato, R.I., Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm. Res. 26 (2009), 2081–2092.
29. [29] Mohamed, E.A., Zhao, Y., Meshall, M.M., Remsberg, C.M., Borg, T.M., Foda, A.M.M., Takemoto, J.K., Sayre, C.L., Martinez, S.E., Davies, N.M., Forrest, M.L., Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(d,l-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J. Pharm. Sci. 101 (2012), 3787–3798.
30. [30] Blanco, E., Bey, E.A., Dong, Y., Weinsberg, B.D., Suttion, D.M., Boothman, D.A., Gao, J., β-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against nqo1-overexpressing tumor cells. J. Control. Release 122 (2007), 365–374.
31. [31] Richter, A., Olbrich, C., Krause, M., Kissel, T., Solubilization of sagopilone, a poorly water-soluble anticancer drug, using polymeric micelles for parenteral delivery. Int. J. Pharm. 389 (2010), 244–253.
32. [32] Wyche, T.P., Dammalapati, A., Cho, H., Harrison, A.D., Kwon, G.S., Shen, H., Bugni, T.S., Jaskula-Sztul, R., Thiocoraline activates the notch pathway in carcinoids and reduces tumor progression in vivo. Cancer Gene Ther. 21 (2014), 518–525.
33. [33] Ramakingam, S.S., Egorin, M.J., Ramanathan, R.K., Remick, S.C., Sikorski, R.P., Lagattuta, T.F., Chatta, G.S., Friedland, D.M., Stoller, R.G., Potter, D.M., Percy Ivy, S., Belani, C.P., A phase I study with 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin. Cancer Res. 14 (2008), 3456–3461.
34. [34] Liu, J., Xiao, Y., Allen, C., Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J. Pharm. Sci. 93 (2004), 132–143.
35. [35] Nagarajan, R., Barry, M., Ruckenstein, E., Unusual selectivity in solubilization by block copolymer micelles. Langmuir 2 (1986), 210–215.
36. [36] Hrkach, J., Von Hoff, D., Ali, M.M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B., Sabnis, A., Schnipper, E., Song, J.L., Song, Y.H., Summa, J., Tompsett, D., Troiano, G., Van Geen Hoven, T., Wright, J., LoRusso, P., Kantoff, P.W., Bander, N.H., Sweeney, C., Farokhzad, O.C., Langer, R., Zale, S., Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differential pharmacological profile. Sci. Transl. Med., 4, 2012 (128ra39).
37. [37] Ramaswamy, M., Zhang, X., Burt, H.M., Wasan, K.M., Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 86 (1997), 460–464.
38. [38] Chen, H., Kim, S., He, W., Wang, H., Low, P.S., Park, K., Chen, J.-X., Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo förster resonance energy transfer imaging. Langmuir 24 (2008), 5213–5217.
39. [39] Yamamoto, Y., Nagasaki, Y., Kato, Y., Sugiyama, Y., Kataoka, K., Long-circulating poly(ethylene glycol)-poly(d,l-lactide) block copolymer micelles with modulated surface charge. J. Control. Release 77 (2001), 27–38.
40. [40] Yoo, H.S., Park, T.G., Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J. Control. Release 70 (2001), 63–70.
41. [41] Ma, X., Huang, X., Moore, Z., Huang, G., Kilgore, J.A., Wang, Y., Hammer, S., Williams, N.S., Boothman, D.A., Gao, J., Esterase-activatable β-lapachone prodrug micelles for nqo1-targeted lung cancer therapy. J. Control. Release 200 (2015), 201–211.
42. [42] Blols, J., Smith, A., Josephson, L., The slow death response when screening chemotherapeutic agents. Cancer Chemother. Pharmacol. 68 (2011), 795–803.
43. [43] Stirland, D.L., Nichols, J.W., Miura, S., Bae, Y.H., Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J. Control. Release 172 (2013), 1045–1064.
44. [44] Yang, D., Yu, L., Van, S., Clinically relevant anticancer polymer paclitaxel therapeutics. Cancer 3 (2011), 17–42.
45. [45] Kim, S.C., Kim, D.W., Shim, Y.H., Bang, J.S., Oh, H.S., Kim, S.W., Seo, M.H., In vivo evaluation of polymeric micelle paclitaxel formulation: toxicity and efficacy. J. Control. Release 72 (2001), 191–202.
46. [46] Sparreboom, A., Baker, S.D., Verwell, J., Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?. J. Clin. Oncol. 23 (2005), 7765–7767.
47. [47] https://clinicaltrials.gov/ct2/show/NCT02064829.
48. [48] Sparreboom, A., Scripture, C.D., Trieu, V., Williams, P.J., De, T., Young, A., Beals, B., Figg, W.D., Hawkins, M., Desai, N., Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (abi-007) and paclitaxel formulated in cremophor (taxol). Clin. Cancer Res. 11 (2005), 4136–4143.
49. [49] Desai, N., De, T., Ci, S., Louie, L., Trieu, V., Characterization and in vitro/in vivo dissolution of nab-paclitaxel nanoparticles. Cancer Res., 68, 2008, 5624.
50. [50] Kratz, F., A clinical update of using albumin as a drug vehicle — a commentary. J. Control. Release 190 (2014), 331–336.
51. [51] Stoltzing, O., Dual-targeting of mTOR and HSP90 for cancer therapy. Cell Cycle 9 (2010), 2051–2052.
52. [52] Perego, P., Cossa, G., Zuco, V., Zunino, F., Modulation of cell sensitivity to antitumor agents by targeting survival pathways. Biochem. Pharmacol. 80 (2010), 1459–1465.
53. [53] Hurvitz, S.A., Andre, F., Jiang, Z., Shao, Z., Mano, M.S., Neciosup, S.P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., Dreosti, L.M., Burris, H.A., Toi, M., Buyse, M.E., Cabaribere, D., Lindsay, M.-A., Rao, S., Pacaud, L.B., Taran, T., Slamon, D., Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with her2-positive advanced breast cancer (bolero-1): a phase 3, randomized, double-blind, multicentre trial. Lancet Oncol. 16 (2015), 816–829.
54. [54] Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M.E., Sugarman, S., Ma, W., Patit, S., Norton, L., Hannah, A.L., Hudis, C., Hsp90 inhibition is effective in breast cancer: a phase ii trial of tanespimycin (17-aag) plus trastuzumab in patients with her2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17 (2011), 5132–5139.
55. [55] Hasenstein, J.R., Shin, H.-C., Kasmerchak, K., Buehler, D., Kwon, G.S., Kozak, K.R., Antitumor activity of triolimus: a novel multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-aag. Mol. Cancer Ther. 11 (2012), 1–10.
56. [56] Shin, H.-C., Cho, H., Lai, T.C., Kozak, K.R., Kolesar, J.M., Kwon, G.S., Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J. Control. Release 163 (2012), 93–99.
57. [57] Lu, D., Wientjes, G., Lu, Z., Au, J.L.-S., Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 322 (2007), 80–88.
58. [58] Gonzalez-Angulo, A.M., Hortobagyi, G.N., Optimal schedule of paclitaxel: weekly is better. J. Clin. Oncol. 26 (2008), 1585–1587.
59. [59] Cho, H., Kwon, G.S., Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging. ACS Nano 5 (2011), 8721–8729.
60. [60] Zentner, G.M., Rathi, R., Shih, C., McRea, J.C., Seo, M.-H., Oh, H., Rhee, B.G., Mestecky, J., Moldoveanu, Z., Morgan, M., Weitman, S., Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release 73 (2001), 203–215.
61. [61] Wolinsky, J.B., Colson, Y., Grinstaff, M.W., Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J. Control. Release 159 (2012), 14–26.
62. [62] Elstad, N.L., Fowers, K.D., Oncogel (regel/paclitaxet) — clinical applications for a novel paclitaxel delivery system. Adv. Drug Deliv. Rev. 61 (2009), 785–794.
63. [63] Matthes, K., Mino-Kenudson, M., Sahani, D.V., Holalkere, N., Fowers, K.D., Rathi, R., Brugge, W.R., EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in porcine pancreas. Gastrointest. Endosc. 65 (2007), 448–453.
64. [64] Lee, D.S., Shim, M.S., Kim, S.W., Lee, H., Park, I., Chang, T., Novel thermoreversible gelation of biodegradable PLGA-block-PEO-block-PLGA triblock copolymers in aqueous solution. Macromol. Rapid Commun. 22 (2001), 587–592.
65. [65] DuVall, G.A., Tarabar, D., Seidel, R.H., Elstad, N.L., Fowers, K.D., Phase 2: a dose-escalation study of Oncogel (regel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anti-Cancer Drugs 20 (2009), 89–95.
66. [66] Tyler, B., Fowlers, K.D., Li, K.W., Recinos, V.R., Caplan, J.M., Hdeib, A., Grossman, R., Basaldella, L., Bekelis, K., Pradilla, G., Legnani, F., Brem, H., A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J. Neurosurg. 113 (2010), 210–217.
67. [67] Vellimana, A.K., Recinos, V.R., Hwang, L., Fowers, K.D., Li, K.W., Zhang, Y., Okonma, S., Eberhart, C.G., Brem, H., Tyler, B.M., Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J. Neuro-Oncol. 111 (2013), 229–236.
68. [68] Cho, H., Kwon, G.S., Thermosensitive poly(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery. J. Drug Target. 22 (2014), 669–677.